Eli Lilly – EMC²

Learning Portfolio: Eli Lilly – Diabetes Treatment Update – Diabetes – Insulin and GLP 1

Topic: Diabetes Treatment Update – Diabetes – Insulin and GLP 1                                            

Points to be discussed

  1. Reviews the physiology of GLP-1 and outlines the benefits and evolution of the GLP-1 receptor agonist class, for treatment of Type 2 Diabetes patients.
  2. Introduces the once-weekly GLP-1 receptor agonist dulaglutide, and provides an overview of its efficacy and safety clinical data from the AWARD trial program
  3. Reviews the evolution of cardiovascular outcomes trials for GLP1-RAs and outlines the primary prevention demonstrated by dulaglutide in the REWIND study.

Speaker: Dr Emmanuel Danso  

Date: 28 June 2022

Time 13h30 – 14h30

TRULICITY – SRN_CV Benefits_Sept 2021Download

Loading